Legal & General Group Plc increased its stake in Twist Bioscience Corporation (NASDAQ:TWST – Free Report) by 36.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 171,206 shares of the company’s stock after purchasing an additional 45,920 shares during the quarter. Legal & General Group Plc’s holdings in Twist Bioscience were worth $5,431,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. ARK Investment Management LLC boosted its holdings in Twist Bioscience by 5.1% in the third quarter. ARK Investment Management LLC now owns 6,726,808 shares of the company’s stock worth $189,292,000 after purchasing an additional 326,367 shares during the last quarter. Artisan Partners Limited Partnership boosted its holdings in Twist Bioscience by 26.7% in the third quarter. Artisan Partners Limited Partnership now owns 6,410,900 shares of the company’s stock worth $180,403,000 after purchasing an additional 1,349,867 shares during the last quarter. William Blair Investment Management LLC boosted its holdings in Twist Bioscience by 43.7% in the fourth quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company’s stock worth $188,874,000 after purchasing an additional 1,812,146 shares during the last quarter. EdgePoint Investment Group Inc. boosted its holdings in Twist Bioscience by 71.1% in the third quarter. EdgePoint Investment Group Inc. now owns 4,082,319 shares of the company’s stock worth $114,876,000 after purchasing an additional 1,696,377 shares during the last quarter. Finally, Millennium Management LLC boosted its holdings in Twist Bioscience by 151.5% in the third quarter. Millennium Management LLC now owns 1,793,850 shares of the company’s stock worth $50,479,000 after purchasing an additional 1,080,722 shares during the last quarter.
Insiders Place Their Bets
In other Twist Bioscience news, Director Melissa A. Starovasnik sold 1,000 shares of the company’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $51.00, for a total value of $51,000.00. Following the transaction, the director directly owned 25,722 shares in the company, valued at $1,311,822. This represents a 3.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert Chess sold 10,000 shares of the company’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $47.00, for a total transaction of $470,000.00. Following the completion of the transaction, the director owned 21,084 shares in the company, valued at $990,948. This represents a 32.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 42,768 shares of company stock worth $2,390,888. 3.08% of the stock is owned by company insiders.
Twist Bioscience Stock Performance
Twist Bioscience (NASDAQ:TWST – Get Free Report) last released its quarterly earnings data on Monday, May 4th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.22). The company had revenue of $110.72 million during the quarter, compared to analysts’ expectations of $107.64 million. Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. Twist Bioscience’s quarterly revenue was up 19.3% on a year-over-year basis. During the same period last year, the firm earned ($0.66) earnings per share. On average, equities research analysts forecast that Twist Bioscience Corporation will post -1.99 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several analysts have recently commented on TWST shares. Barclays raised their price objective on shares of Twist Bioscience from $55.00 to $65.00 and gave the company an “overweight” rating in a research report on Monday, May 4th. Robert W. Baird lifted their price target on shares of Twist Bioscience from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Tuesday, May 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a report on Friday, March 27th. Guggenheim lifted their price target on shares of Twist Bioscience from $55.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Finally, Leerink Partners set a $80.00 price target on shares of Twist Bioscience in a report on Friday, May 22nd. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $58.00.
Read Our Latest Analysis on TWST
Twist Bioscience Company Profile
Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.
At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.
Read More
- Five stocks we like better than Twist Bioscience
- These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?
- 3 Stocks Under $20 to Buy Before a Broader Market Rally
- Petco Faces Tough Competition, But Momentum Is Building
- The Lock-In Effect Is Real—These 3 Homebuilders Are Betting on It
Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Corporation (NASDAQ:TWST – Free Report).
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
